Institutional shares held 3.35 Million
46.5K calls
6.3K puts
Total value of holdings $770K
$10K calls
$1K puts
Market Cap $14.2M
61,524,500 Shares Out.
Institutional ownership 5.45%
# of Institutions 38


Latest Institutional Activity in BLRX

Top Purchases

Q3 2024
Morgan Stanley Shares Held: 198K ($45.4K)
Q3 2024
Xtx Topco LTD Shares Held: 44.1K ($10.2K)
Q3 2024
Pvg Asset Management Corp Shares Held: 157K ($36.2K)
Q3 2024
Atria Investments LLC Shares Held: 134K ($30.8K)
Q3 2024
Envestnet Asset Management Inc Shares Held: 239K ($55K)

Top Sells

Q3 2024
Alyeska Investment Group, L.P. Shares Held: 866K ($199K)
Q3 2024
Susquehanna International Group, LLP Shares Held: 18K ($4.15K)
Q3 2024
Geneos Wealth Management Inc. Shares Held: 4.5K ($1.04K)
Q3 2024
Wells Fargo & Company Shares Held: 35K ($8.06K)
Q3 2024
Values First Advisors, Inc. Shares Held: 198K ($45.4K)

About BLRX

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.


Insider Transactions at BLRX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on BLRX

Follow BioLineRx Ltd. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BLRX shares.

Notify only if

Insider Trading

Get notified when an Bio Line Rx Ltd. insider buys or sells BLRX shares.

Notify only if

News

Receive news related to BioLineRx Ltd.

Track Activities on BLRX